AbbVie Inc. Consolidated Net Income/Loss

Consolidated Net Income/Loss of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Consolidated Net Income/Loss growth rates and interactive chart.


Highlights and Quick Summary

  • Consolidated Net Income/Loss for the quarter ending December 30, 2019 was $2.8 Billion (a 48.67% increase compared to previous quarter)
  • Year-over-year quarterly Consolidated Net Income/Loss increased by 14.05%
  • Annual Consolidated Net Income/Loss for 2019 was $7.88 Billion (a 38.6% increase from previous year)
  • Annual Consolidated Net Income/Loss for 2018 was $5.69 Billion (a 7.12% increase from previous year)
  • Annual Consolidated Net Income/Loss for 2017 was $5.31 Billion (a -10.82% decrease from previous year)
  • Twelve month Consolidated Net Income/Loss ending December 30, 2019 was $7.88 Billion (a 142.15% increase compared to previous quarter)
  • Twelve month trailing Consolidated Net Income/Loss increased by 47.05% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$7.88 Billion $3.26 Billion $4.12 Billion $5.36 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Consolidated Net Income/Loss of AbbVie Inc.

Most recent Consolidated Net Income/Lossof ABBV including historical data for past 10 years.

Interactive Chart of Consolidated Net Income/Loss of AbbVie Inc.

AbbVie Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $2,801.0 $1,884.0 $741.0 $2,456.0 $7,882.0
2018 $-1,826.0 $2,747.0 $1,983.0 $2,783.0 $5,687.0
2017 $52.0 $1,631.0 $1,915.0 $1,711.0 $5,309.0
2016 $1,391.0 $1,598.0 $1,610.0 $1,354.0 $5,953.0
2015 $1,517.0 $1,239.0 $1,366.0 $1,022.0 $5,144.0
2014 $-810.0 $506.0 $1,098.0 $980.0 $1,774.0
2013 $1,128.0 $964.0 $1,068.0 $968.0 $4,128.0
2012 $1,540.0 $1,585.0 $1,267.0 $883.0 $5,275.0
2011 $1,157.0 $13.0 $1,540.0 $723.2 $3,433.0
2010 $4,178.0
2009 $4,636.52

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.